Search

The collagenase production of cultured skin fibroblasts from Scandinavian families with dominant (D-EBD) and recessive (R-EBD) epidermolysis bullosa dystrophica has been investigated. Heterogeneity as a result of body location origin has been ruled out as fibroblasts obtained from predilection sites produce the same amount of immunoreactive collagenase as those obtained from non-predilection sites of the same subjects. Large variations in in vitro collagenase production were found between individuals and families. Within the R-EBD group, four out of eighteen patients showed an in vitro elevated level of immunoreactive collagenase compared to their healthy relatives, other EB types, and the control group. This shows that an in vitro elevated collagenase production is not a marker for the entire disease group and that the disease denoted as R-EBD probably is etiologically and pathogenetically heterogeneous. [ABSTRACT FROM AUTHOR]

The use of gelatinase expression in dermal fibroblast cultures as a marker for generalized epidermolysis bullosa simplex (D-EBS-Köbner) has been tested. None of the 6 Köbner patients tested (from 3 families) produced reduced amounts of gelatinase compared with their healthy relatives and other control groups. This shows that a reduced production of gelatinase from dermal fibroblasts is not uniformly a marker for D-EBS-K. [ABSTRACT FROM AUTHOR]

The article focuses on clinical heterogeneity in epidermolysis bullosa (EB). A recent article presented an extensive review on the role of anchoring fibril changes in dystrophic epidermolysis bullosa, summarizing electron microscopic, biochemical and other evidence. Included were highly relevant points on clinical diagnosis, not the least of which was the difficulty in discriminating the local forms of the recessive type from sporadic dominant mutant cases. The focus in the article is on the clinical variations in different categories of EB, their possible causations, and consequences.